BioMarin lands 20% Yuviwel royalty in Ascendis patent settlement
BioMarin (BMRN) settled a patent dispute with Ascendis (ASND), securing a 20% royalty on Yuviwel US sales and 18% on EU, Brazil, and South Korea sales through 2030. Yuviwel reported EUR 8M revenue in Q2 2026. The deal covers current and potential indications, including achondroplasia and hypochondroplasia. BioMarin's Voxzogo seeks full FDA approval by February 2027, with positive Phase III results for hypochondroplasia reported in May 2026.
How this was made
The 30-second read
Why it matters
Both companies gain clarity: BioMarin adds royalty income; Ascendis removes litigation risk but assumes a cost.
Market read
First‑report royalty settlement introduces new cash‑flow dynamics for two listed biotech firms.
What to watch
Future approval of infigratinib could introduce competition that bypasses the royalty stream.
Background
The settlement resolves a multi‑year patent dispute over CNP analogs used in skeletal dysplasia treatments.
Ticker impact
BioMarin secured a 20% US royalty and 18% EU, Brazil, South Korea royalty on Ascendis' Yuviwel sales.
Potential upside as royalty income boosts future cash flow.
Royalty agreement is a material, first‑report deal that directly benefits BioMarin's earnings.
Ascendis agreed to pay BioMarin royalties on Yuviwel net sales in multiple regions.
Possible downside pressure as royalty expense reduces profitability.
The settlement introduces a recurring expense for Ascendis, a material new liability.
Market effects
Rare‑disease biotech sector may see increased focus on royalty deals as a monetization path.
US and EU markets see a new cross‑border royalty arrangement affecting biotech valuations.
Highlights the growing importance of intellectual‑property licensing in rare‑disease drug commercialization.
Counterpoint
The royalty burden could limit Ascendis' pricing power, outweighing any competitive advantage from the settlement.
Key entities
- companyBioMarin Pharmaceutical Inc.
US biotech focused on rare diseases.
- companyAscendis Pharma A/S
Denmark‑based developer of Yuviwel.
